SEC Filing Summary

On September 11, 2026, Harvard Apparatus Regenerative Technology, Inc. (HRGN) entered into Securities Purchase Agreements with certain investors for a private placement of 2,703,727 shares of common stock at $1.05 per share. The reporting person, He Junli (CEO), acquired 683,725 shares through the conversion of $717,911 in outstanding principal and accrued interest from bridge promissory notes issued on April 14, May 13, and July 16, 2026. These notes were converted at the same $1.05 per share price, and the notes were cancelled. Additionally, He Junli purchased 361,905 shares for $380,000 in cash in the same private placement. Further, between September 15 and September 23, 2026, 6,725 shares were acquired at a weighted average price of $2.15. The bridge notes were convertible upon a qualified equity financing, with the conversion price fixed at $1.05 per share upon the closing of the private placement on September 11, 2026. The notes were scheduled to mature on the earlier of a subsequent capital raise or the first anniversary of their issue date.